ELF5 and cancer: Kalyuga et al. reported that tamoxifen-resistant luminal cancer cell lines increased ELF5 expression, and increased expression of ELF5 in luminal cancer cell lines drives a basal-like signature that leads to the suppression of sensitivity to estrogen [25].